Non-Invasive Preeclampsia Screening and Biobank
ConditionPreeclampsia (PE)
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexFemale
Age18+
SponsorSequenom, Inc.
About this trial
Women pregnant between 11-14 weeks gestation will be enrolled with blood samples collected to evaluate for preeclampsia.
Eligibility criteria
Qualifiers
Subject is female and 18 years of age and older;
Subject provides a signed and dated informed consent;
Subject is pregnant with a singleton pregnancy at ≥11.0 - ≤14.0 weeks' gestation;
Subject agrees to provide the Sponsor access to any prenatal and postnatal screening or diagnostic test results and supporting data;
Disqualifiers
Subject is unlikely to return for second and third trimester testing;
Subject is unlikely to have pregnancy outcome data available;
Previous sample donation under this protocol with the same pregnancy;
Subject is participating in a blinded aspirin study or taking unknown doses of aspirin.
Trial design
Treatments tested in this trial
- Not listed
Trial groups
6,550 Participants
are grouped into 1 trial groupSponsors and collaborators
Sequenom, Inc.
Lead sponsor
Rutgers Robert Wood Johnson Medical School
Collaborator
Laboratory Corporation of America
Collaborator
Source ClinicalTrials.gov